DFX Intelligence
Borrowers
48 borrower groups currently held, grade A and BWhat a borrower group isA borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.
Industry as filed contains “Health Care Equipment & Supplies” (remove)
Start from
48 borrower groups
| Borrower | Sponsor | BDCs | Principal held | On cost | Spread | Next maturity | First seen |
|---|---|---|---|---|---|---|---|
| PerkinElmer U.S. LLC Life sciences | unattributed | 16 | at least $705M | 100c | 2 pts | Mar 1, 2029 | Mar 31, 2023 |
| Zeus Company LLC Life sciences | unattributed | 7 | at least $428M | 94c | 3 pts | Feb 28, 2030 | Dec 31, 2023 |
| Gula Buyer Inc Life sciences | unattributed | 3 | at least $216M | 101c | 2 pts | Oct 1, 2031 | Dec 31, 2024 |
| H••••••• I•• Life sciences | unattributed | 10 | at least $173M | 99c | 1 pts | Apr 1, 2033 | Sep 30, 2025 |
| V•••••• S••••• B•••• I• I•• Life sciences | unattributed | 1 | at least $147M | 100c | n/a | Jan 30, 2032 | Mar 31, 2025 |
| C•••••• A••••••••• L•• Life sciences | unattributed | 7 | at least $135M | 94c | 14 pts | Oct 11, 2029 | Dec 31, 2022 |
| H••••••• T•••••• I•• Life sciences | unattributed | 3 | at least $110M | 102c | 2 pts | Nov 28, 2031 | Sep 30, 2024 |
| Y•• L•• Life sciences | Sponsor not establishedpossible: L••••• C•••••• P••••••• (a company of this name is on the sponsor's portfolio page) | 17 | at least $88.1M | 100c | 2 pts | Dec 1, 2029 | Dec 31, 2021 |
| R••••••••• L•• Life sciences | unattributed | 15 | at least $87.4M | 100c | 0 pts | Jun 1, 2031 | Dec 31, 2021 |
| T••• L••••• P•••••••• I•• Life sciences | unattributed | 15 | at least $84.2M | 100c | 3 pts | Dec 1, 2029 | Dec 31, 2023 |
| R••••••••• M••••••• L•• Life sciences | unattributed | 4 | at least $68.9M | 100c | 0 pts | Jun 21, 2027 | Sep 30, 2022 |
| C••• B••••••• L•• Life sciences | unattributed | 9 | at least $61.4M | 100c | 0 pts | Apr 29, 2033 | Sep 30, 2022 |
| E•••• P•••••••• L•• Life sciences | unattributed | 2 | at least $50.7M | 92c | 0 pts | Dec 6, 2027 | Dec 31, 2022 |
| S••••• G•••• H•••••••• L•• Life sciences | unattributed | 7 | at least $49.5M | 101c | 1 pts | Jun 16, 2027 | Dec 31, 2021 |
| M•••••• G•••••••• L•• Life sciences | unattributed | 2 | at least $43.4M | 101c | 1 pts | Apr 26, 2028 | Mar 31, 2022 |
| O•••••••• H•••••••• I•• Life sciences | unattributed | 1 | at least $31.4M | 56c | n/a | Jul 31, 2026 | Dec 31, 2022 |
| D•••••••• H•••••• I•• Life sciences | Sponsor not establishedpossible: W••••••• H••••• I••••••••• L•• (a company of this name is on the sponsor's portfolio page) | 3 | at least $30.7M | 101c | 1 pts | Nov 1, 2030 | Dec 31, 2024 |
| C••••••• S••••• L•• Life sciences | Sponsor not establishedpossible: B••••• W••• C••••••• L•• (a company of this name is on the sponsor's portfolio page) | 3 | at least $25.1M | 103c | n/a | Mar 31, 2030 | Mar 31, 2025 |
| C•••••• H•••••••• B•••• G••• Life sciences | unattributed | 1 | at least $21.1M | 105c | n/a | Jun 28, 2030 | Jun 30, 2023 |
| N••••••••• I•• Life sciences | unattributed | 1 | at least $20.0M | 100c | n/a | May 27, 2030 | Jun 30, 2025 |
| F••••••••• N• Life sciences | unattributed | 1 | at least $20.0M | 100c | n/a | May 7, 2032 | Mar 31, 2025 |
| V••••••••• I•• Life sciences | unattributed | 3 | at least $19.8M | 99c | 0 pts | Sep 30, 2027 | Dec 31, 2022 |
| U••••••••• Life sciences | unattributed | 1 | at least $19.7M | 100c | n/a | May 24, 2029 | Dec 31, 2024 |
| L•• I••••••••• L•• Life sciences | unattributed | 2 | at least $19.4M | 102c | n/a | Nov 3, 2027 | Dec 31, 2024 |
| N•••• S••••••• I•• Life sciences | unattributed | 2 | at least $17.8M | 99c | 2 pts | Jan 7, 2031 | Mar 31, 2025 |
| H• P••••••••• L•• Life sciences | unattributed | 2 | at least $13.6M | 100c | 0 pts | Jan 29, 2031 | Mar 31, 2026 |
| P•••••• T•••• T•••• M•••••• L•• Life sciences | unattributed | 2 | at least $12.2M | 99c | 0 pts | Jun 12, 2031 | Mar 31, 2026 |
| C• M•••••• B• I•• A••••••••• L•• Life sciences | unattributed | 2 | at least $11.9M | 100c | 0 pts | Nov 1, 2027 | Dec 31, 2025 |
| P••••••• O••••••• M•••• 2• L•• Life sciences | unattributed | 2 | at least $11.6M | 100c | 1 pts | Jul 17, 2028 | Dec 31, 2022 |
| J•••••• P••••••• C••• C••• Life sciences | unattributed | 6 | at least $8.8M | 100c | n/a | Mar 1, 2028 | Feb 29, 2024 |
| C••••••••• H•••••• I•• Life sciences | unattributed | 4 | at least $8.7M | 101c | n/a | Mar 31, 2031 | Dec 31, 2021 |
| E•• O••• 1• L•• Life sciences | unattributed | 2 | at least $8.5M | 92c | n/a | Mar 26, 2031 | Sep 30, 2025 |
| S••••••• L•• Life sciences | unattributed | 2 | at least $8.5M | 98c | 1 pts | Jun 12, 2028 | Dec 31, 2022 |
| A•• H••••••••• I•• Life sciences | unattributed | 1 | at least $8.0M | 96c | n/a | Mar 8, 2028 | Dec 31, 2023 |
| P••••••••• I•• Life sciences | unattributed | 1 | at least $6.5M | 101c | n/a | Dec 30, 2030 | Dec 31, 2024 |
| F• D•• B••••• I•• Life sciences | unattributed | 3 | at least $4.7M | 101c | n/a | Oct 11, 2030 | Dec 31, 2023 |
| C•••• H••••••••• C••• B••••••• L•• Life sciences | unattributed | 2 | at least $3.9M | 100c | n/a | Apr 29, 2033 | Sep 30, 2025 |
| H••••• M••••• S•• I•• Life sciences | unattributed | 2 | at least $2.9M | 98c | n/a | Apr 7, 2033 | Mar 31, 2026 |
| C•••• C••••••••• Life sciences · grade B | unattributed | 1 | at least $2.5M | 100c | n/a | Jun 1, 2031 | Mar 31, 2022 |
| S••••• R••••••••• I• L•• Life sciences | unattributed | 2 | at least $2.3M | 101c | n/a | Jun 30, 2028 | Dec 31, 2025 |
| M••••••• M••••••••• T•• H••••••• I•• Life sciences | unattributed | 4 | at least $1.9M | 100c | n/a | Jun 9, 2032 | Jun 30, 2026 |
| C••••••••• I•• Life sciences | unattributed | 1 | unknown | n/a | n/a | unstated | Dec 31, 2022 |
| C•••••••• O••••••••• I•• Life sciences | unattributed | 1 | unknown | n/a | n/a | unstated | Dec 31, 2022 |
| M••••••••• I•• Life sciences | unattributed | 3 | unknown | n/a | n/a | unstated | Dec 31, 2022 |
| R••••• I•••••••• Life sciences | unattributed | 1 | unknown | n/a | n/a | unstated | Dec 31, 2023 |
| U•••• H• P••••••••• L•• Life sciences | unattributed | 1 | unknown | n/a | n/a | unstated | Mar 31, 2026 |
| V•••• C•••••• L•• Life sciences | M••••• A•••• M••••••••• L• inferred | 1 | unknown | n/a | n/a | unstated | Dec 31, 2022 |
| V••••••• H•••••••• L•• Life sciences | unattributed | 3 | unknown | n/a | n/a | unstated | Dec 31, 2023 |
Page 1 of 1
The borrower, lender and sponsor names past the first 3 rows are hidden. Open a row to reveal that record with a free account (5 a month), or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source is public either way.